Background:To explore the effectiveness,safety,and efficacy of the robot-assisted surgery in the radical resection of pancreatic ductal adenocarcinoma(PDAC).Methods:The clinical data of 72 patients with PDAC who underwent radical resection using the da Vinci Surgical System from April 2010 to December 2014 were retrospectively analyzed.Results:Among these 72 patients,three were converted to conventional laparotomy due to the vascular invasion or due to the difficulties in tissue isolation from the surrounding organs.Among 39 patients who underwent the pancreatoduodenectomy,the average operative time was 395.3±118.8 min,and the mean intra-operative blood loss was 447.3±269.9 m L.Among 31 patients who underwent the distal pancreatectomy(DP),the average operative time was 185.5±74.1 min,and the mean intra-operative blood loss was 267.1±305.3 m L.In two patients who received the middle pancreatectomy(MP),the average operative time was 225 min and mean intra-operative blood loss was 100 m L.Among all the 72 patients,an average of 4.2±2.6 lymph nodes were dissected,with an average hospital stay of 22.6±10.7 days.Complications were observed in 18 patients,which included pancreatic fistula(n=11),bile leak(n=5),anastomotic bleeding(n=2),pancreatic fistula complicated with portal vein thrombosis(n=1),and anastomotic bleeding complicated with acute renal failure(n=1).Except that one patient died due to post-operative bleeding and acute renal failure,all the other patients were cured after conservative treatment.These 72 patients were followed for 1-45(15.6±5.8) months,during which 10 patients died.Eleven patients suffered from recurrence or metastasis,among which 6 had local recurrence,4 had liver metastasis,and 1 had ascites accompnaied with incision site tumor metastasis.Conclusions:Radical resection of PDAC by robotic surgical system is safe and feasible.It has less surgical trauma and enables faster post-operative recovery,and therefore can achieve the lymph node dissection scope and tumor resection margin required by the standards of radical resection for pancreatic cancer.Nevertheless,its long-term efficacy requires further validation. Background: To explore the effectiveness, safety, and efficacy of the robot-assisted surgery in the radical resection of pancreatic ductal adenocarcinoma (PDAC). Methods: The clinical data of 72 patients with PDAC who underwent radical resection using the da Vinci Surgical System from April 2010 to December 2014 were retrospectively analyzed. Results: Among these 72 patients, three were converted to conventional laparotomy due to the vascular invasion or due to the difficulties in tissue isolation from the surrounding organs. Among 39 patients who underwent the pancreatoduodenectomy, the average operative time was 395.3 ± 118.8 min, and the mean intra-operative blood loss was 447.3 ± 269.9 m L. Among 31 patients who underwent the distal pancreatectomy (DP), the average operative time was 185.5 ± 74.1 min, and the mean intra- operative blood loss was 267.1 ± 305.3 m L. In two patients who received the middle pancreatectomy (MP), the average operative time was 225 min and mean intra-operative blood loss was 100 m L.Among all the 72 patients, an average of 4.2 ± 2.6 lymph nodes were dissected, with an average hospital stay of 22.6 ± 10.7 days. Applications were observed in 18 patients, which included pancreatic fistula (n = 11), bile leak (n = 5), anastomotic bleeding (n = 2), pancreatic fistula complicated with portal vein thrombosis (n = 1), and anastomotic bleeding complicated with acute renal failure operative bleeding and acute renal failure, all the other patients were cured after conservative treatment. These 72 patients were followed for 1-45 (15.6 ± 5.8) months, during which 10 patients died. Eleven patients suffered from recurrence or metastasis, among which 6 had local recurrence, 4 had liver metastasis, and 1 had ascites accompnaied with incision site tumor metastasis. Confc: Radical resection of PDAC by robotic surgical system is safe and feasible. It has less surgical trauma and enables faster post-operative recovery, and therefore can achieve the lymph node di ssection scope and tumor resection margin required by the standards of radical resection for pancreatic cancer. promising, its long-term efficacy requires further validation.